Recent Posts
- AbSci Announces $65 Million Financing Led by Casdin Capital
- Alpha Cancer Technologies to License AbSci’s SoluPro Strain for the Expression of Alpha-Fetoprotein
- AbSci Closes $15.4 M in Series D Funding to Accelerate Growth and Scale Disruptive Protein PrintingTM Technology, Announces Exclusive Co-Marketing Partnership with KBI Biopharma
- 10 Life Science Innovators Under 40 to Watch
- AbSci will attend BioEurope Spring – March 25–27, 2019